Saturday, September 23, 2023
Saturday, September 23, 2023

Aidoc Reports FDA Clears Complete AI Stroke Package

Aidoc provides AI solutions for radiologists. Today they announced that the US Food and Drug Administration (FDA) has cleared its AI solution for flagging Large-Vessel Occlusion (LVO) in head CTA scans, marking Aidoc’s fourth FDA-cleared AI package.

Combined with Aidoc’s previously-cleared AI module for flagging and prioritizing intracranial hemorrhage, together they provide a comprehensive AI package for the identification and triage of both ischemic and hemorrhagic stroke in CTs, speeding time to treatment when every minute counts.

“Stroke is the ultimate time-critical condition,” said Dr. Marcel Maya, Co-chair Department of Imaging, Cedars-Sinai Medical Center. “The faster we can identify, diagnose and treat it, the better the outcome for patients. Aidoc’s comprehensive stroke package flags both large vessel occlusion and hemorrhages inside our existing workflows, ensuring we can diagnose stroke faster and decide on the best course of treatment. We’re already seeing how this has a positive impact on department efficiency and patient length of stay.”

5% of all deaths in the USA are from stroke, and it is one of the major causes of disability. During a stroke 1.9 million neurons and 14 billion synapses die each minute[1], making fast diagnosis and treatment critical. Improved medical imaging and better treatments have revolutionized stroke care, making it possible to clear occlusions in the brain’s arteries using thrombolysis or mechanical thrombectomy; however, hemorrhage must be ruled out before administering a thrombolytic agent. The faster the time from door-to-treatment for patients suffering from stroke, the more likely a patient will survive without serious neurological impairment.

Aidoc’s always-on solution continuously scans images for both ischemic and hemorrhagic stroke, automatically moving suspected cases to the top of radiologists’ worklists. Aidoc’s integrated solution provides a single context for radiologists to diagnose both LVO and hemorrhage, so they can quickly decide on the most appropriate course of action. Often, patients are diagnosed with stroke in a smaller facility before being moved to a specialist stroke center for treatment. Aidoc’s combined stroke solution ensures that the diagnosing facility and the stroke center can work together in a coordinated manner to expedite patient care.

Research performed by the University of Rochester Medical Center showed Aidoc’s ability to reduce turnaround time for emergency room patients with intracranial hemorrhage by 36.6%. Research by Yale-New Haven Hospital confirmed Aidoc’s impact in expediting the time to treatment for these critical cases.

“With our fourth 501(k) clearance, Aidoc is leading the way in radiology AI with the most comprehensive FDA-cleared AI triage package,” said Gal Yaniv, MD, Endovascular Neurosurgeon, and Neuroradiologist at Sheba Medical Center and Chief Medical Officer of Aidoc. “I’m proud that Aidoc’s FDA-cleared AI solutions for flagging pulmonary embolism, cervical spine fractures, and intracranial hemorrhage are in full clinical use, saving lives in more than 300 medical centers across the world.”

SourceAidoc
Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

OTHER NEWS

FDA Grants Fast Track Designation to 9MW3011

9MW3011 has been approved to clinical study by NMPA and FDA, respectively. The first person has been dosed in the clinical study in China in March, 2023.

MicuRx receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Contezolid and Contezolid acefosamil

"We are pleased to gain the QIDP and Fast Track designations for DFI as recognition that contezolid and contezolid acefosamil are novel new agents to meet an important unmet need in this common and challenging infection", stated Dr Zhengyu Yuan, Chief Executive Officer at MicuRx. 

Via Nova Therapeutics Announces FDA clearance of Investigational New Drug (IND) Application for VNT-101

"We look forward to evaluating VNT-101 in the clinic," said Don Ganem MD, Co-Founder and CEO of Via Nova Therapeutics. "This is an important step to developing a flu antiviral with a novel mechanism of action, and a milestone for Via Nova Therapeutics as we advance our first compound into the clinic."

FDA OK’s ensoETM for Use in Cardiac Ablations to Reduce Risk of Esophageal Injury

Published studies that have examined the use of ensoETM for this purpose include the pilot eCOOL-AF study, the IMPACT study and a large multi-center analysis of over 25,000 patients (in press at the Journal of the American College of Cardiology: Clinical Electrophysiology). These studies have found up to an 83 percent reduction in esophageal injuries, and a significant reduction in risk of atrioesophageal fistula (AEF), one of the most dreaded complications of ablation procedures.

Annalise.ai Receives FDA Clearance and Breakthrough Device Designation

Annalise.ai has also received FDA Breakthrough Device Designation for its obstructive hydrocephalus software tool. This is the first radiology triage device to be granted Breakthrough status since the inception of the FDA Breakthrough Devices Program.

By using this website you agree to accept Medical Device News Magazine Privacy Policy